Literature DB >> 32571394

Correction to: Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.

Bastiaan Maes1, Cedric Bosteels2, Elisabeth De Leeuw2, Jozefien Declercq2, Karel Van Damme2, Anja Delporte2, Bénédicte Demeyere2, Stéfanie Vermeersch2, Marnik Vuylsteke2, Joren Willaert2, Laura Bollé2, Yuri Vanbiervliet2, Jana Decuypere2, Frederick Libeer2, Stefaan Vandecasteele2, Isabelle Peene2, Bart N Lambrecht2.   

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Entities:  

Year:  2020        PMID： 32571394      PMCID： PMC7306650          DOI： 10.1186/s13063-020-04519-4

Source DB:  PubMed          Journal:  Trials        ISSN： 1745-6215            Impact factor:   2.279


  1 in total

1.  Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.

Authors:  Bastiaan Maes; Cedric Bosteels; Elisabeth De Leeuw; Jozefien Declercq; Karel Van Damme; Anja Delporte; Bénédicte Demeyere; Stéfanie Vermeersch; Marnik Vuylsteke; Joren Willaert; Laura Bollé; Yuri Vanbiervliet; Jana Decuypere; Frederick Libeer; Stefaan Vandecasteele; Isabelle Peene; Bart Lambrecht
Journal:  Trials       Date:  2020-06-03       Impact factor: 2.279
  1 in total
  1 in total

Review 1.  Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients.

Authors:  Rodrigo Pacheco Silva-Aguiar; Diogo Barros Peruchetti; Patricia Rieken Macedo Rocco; Alvin H Schmaier; Patrícia Machado Rodrigues E Silva; Marco Aurélio Martins; Vinícius Frias Carvalho; Ana Acacia Sá Pinheiro; Celso Caruso-Neves
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-12       Impact factor: 5.464
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.